PE105399A1 - PROCEDIMIENTO PARA LA PREPARACION DE DERIVADOS DE 3a-(R)-BENCIL-2-METIL-2,3,3a,4,5,6,7-HEXAHIDRO-PIRAZOLO[4,3-c]PIRIDINA-3-ONA - Google Patents

PROCEDIMIENTO PARA LA PREPARACION DE DERIVADOS DE 3a-(R)-BENCIL-2-METIL-2,3,3a,4,5,6,7-HEXAHIDRO-PIRAZOLO[4,3-c]PIRIDINA-3-ONA

Info

Publication number
PE105399A1
PE105399A1 PE1998000546A PE00054698A PE105399A1 PE 105399 A1 PE105399 A1 PE 105399A1 PE 1998000546 A PE1998000546 A PE 1998000546A PE 00054698 A PE00054698 A PE 00054698A PE 105399 A1 PE105399 A1 PE 105399A1
Authority
PE
Peru
Prior art keywords
alkyl
bencil
methyl
procedure
preparation
Prior art date
Application number
PE1998000546A
Other languages
English (en)
Inventor
Judith Lee Treadway
Bruce Allen Lefker
Charles Kwok-Fung Chiu
Michael Paul Zawistoski
Lydia Codetta Pan
Philip Albert Carpino
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PE105399A1 publication Critical patent/PE105399A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05Dipeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/25Growth hormone-releasing factor [GH-RF] (Somatoliberin)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/02Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/78Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Abstract

SE REFIERE A UN COMPUESTO I, DONDE n Y w SON 0-2; Y ES O o S; R1 ES H, -CN, -(CH2)qN(X6)C(O)X6, -(CH2)qN(X6)C(O)(CH2)t-A1, ENTRE OTROS; R2 ES H, ALQUILO C1-C8; ALQUILO(C CERO-C3)-(CICLOALQUILO C3-C8), ENTRE OTROS; R3 ES A1, ALQUILO C1-C10, ALQUILO (C1-C6)-A1, ENTRE OTROS; R4 ES H, ALQUILO C1-C6 o CICLOALQUILO C3-C7, o R3 Y R4 FORMAN UN CICLOALQUILO C5-C7, CICLOALQUENILO C5-C7, ENTRE OTROS; X4 ES H, ALQUILO C1-C6; o X4 Y R4 FORMAN UN ANILLO DE 5-7 MIEMBROS; R6 ES UN ENLACE o -Z1-(CH2)a-C(X5)(X5a)-(CH2)b-; a Y b SON 0-3; X5 Y X5a SON H, TRIFLUOROMETILO, A1, ENTRE OTROS; Z1 ES UN ENLACE, O o NX2; X2 ES H, ALQUILO C1-C6, ENTRE OTROS; R7 Y R8 SON H, ALQUILO C1-C6 OPCIONALMENTE SUSTITUIDO, ENTRE OTROS; A1 ES CICLOALQUENILO C5-C7, FENILO o ANILLO DE 4-8 MIEMBROS, ENTRE OTROS. UN COMPUESTO PREFERIDO ES 2-AMINO-N-[1-(3a-BENCIL-2-METIL-3-OXO-2,3,3a,4,6,7-HEXAHIDROPIRAZOLO[4,3-c)PIRIDIN-5-IL)-1-(1H-INDOL-3-ILMETIL)-2-OXO-ETIL]-ISOBUTIRAMIDA, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION. EL COMPUESTO I ESTIMULA LA LIBERACION DE LA HORMONA DEL CRECIMIENTO POR LO QUE PUEDE SER UTIL PARA EL TRATAMIENTO DE LA RESISTENCIA A LA INSULINA, TRATAMIENTO O PREVENCION DE LA INSUFICIENCIA CARDIACA CONGESTIVA, OBESIDAD O DEBILIDAD ASOCIADA CON LA EDAD, TRASTORNOS DEL SUENO
PE1998000546A 1997-06-25 1998-06-22 PROCEDIMIENTO PARA LA PREPARACION DE DERIVADOS DE 3a-(R)-BENCIL-2-METIL-2,3,3a,4,5,6,7-HEXAHIDRO-PIRAZOLO[4,3-c]PIRIDINA-3-ONA PE105399A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5079097P 1997-06-25 1997-06-25

Publications (1)

Publication Number Publication Date
PE105399A1 true PE105399A1 (es) 1999-11-04

Family

ID=21967444

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1998000546A PE105399A1 (es) 1997-06-25 1998-06-22 PROCEDIMIENTO PARA LA PREPARACION DE DERIVADOS DE 3a-(R)-BENCIL-2-METIL-2,3,3a,4,5,6,7-HEXAHIDRO-PIRAZOLO[4,3-c]PIRIDINA-3-ONA

Country Status (41)

Country Link
US (3) US6448263B1 (es)
EP (1) EP1000085B1 (es)
JP (2) JP2000514099A (es)
KR (1) KR20010014224A (es)
CN (2) CN1152049C (es)
AP (1) AP1145A (es)
AR (1) AR012256A1 (es)
AT (1) ATE305477T1 (es)
AU (1) AU747510B2 (es)
BG (1) BG104008A (es)
BR (1) BR9810477A (es)
CA (1) CA2294464A1 (es)
CO (1) CO4950621A1 (es)
DE (1) DE69831745T2 (es)
DZ (1) DZ2539A1 (es)
EA (1) EA002089B1 (es)
EG (1) EG21712A (es)
ES (1) ES2248899T3 (es)
HK (1) HK1028051A1 (es)
HN (1) HN1998000088A (es)
HR (1) HRP980361A2 (es)
HU (1) HUP0001922A3 (es)
ID (1) ID24345A (es)
IL (7) IL154116A0 (es)
IN (1) IN189724B (es)
IS (1) IS5275A (es)
MA (1) MA24581A1 (es)
NO (1) NO996205L (es)
NZ (1) NZ500655A (es)
OA (1) OA11242A (es)
PA (1) PA8452601A1 (es)
PE (1) PE105399A1 (es)
PL (1) PL337659A1 (es)
SK (1) SK175699A3 (es)
TN (1) TNSN98113A1 (es)
TR (1) TR199903257T2 (es)
TW (1) TW553943B (es)
UA (1) UA64751C2 (es)
WO (1) WO1998058949A1 (es)
YU (1) YU70199A (es)
ZA (1) ZA985546B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA64751C2 (uk) 1997-06-25 2004-03-15 Пфайзер Продактс Інк. Спосіб лікування інсулінової толерантності речовинами, які посилюють секрецію гормону росту (варіанти) та фармацевтична композиція (варіанти)
UA53716C2 (uk) 1997-06-25 2003-02-17 Пфайзер Продактс Інк. Тартратна сіль заміщеного дипептиду, спосіб її одержання, проміжні сполуки та спосіб їх одержання, фармацевтична композиція (варіанти), спосіб підвищення рівнів ендогенного гормону росту та спосіб лікування або профілактики захворювань (варіанти)
US6541634B2 (en) 1999-02-26 2003-04-01 Pfizer Inc. Process for preparing growth hormone secretagogues
US7721948B1 (en) * 1999-05-25 2010-05-25 Silverbrook Research Pty Ltd Method and system for online payments
EP1132388A3 (en) * 2000-03-09 2004-03-03 Pfizer Products Inc. Hexahydropyrazolo[4,3-c]pyridine metabolites
EP1159964B1 (en) 2000-05-31 2009-10-28 Pfizer Products Inc. Use of growth hormone secretagogues for stimulating gastrointestinal motility
IL145106A0 (en) * 2000-08-30 2002-06-30 Pfizer Prod Inc Intermittent administration of a geowth hormone secretagogue
CA2496687A1 (en) * 2002-09-18 2004-04-01 Centre Hospitalier De L'universite De Montreal (Chum) Ghrh analogues
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
US7828934B2 (en) * 2004-12-21 2010-11-09 Hercules Incorporated Reactive cationic resins for use as dry and wet strength agents in sulfite ion-containing papermaking systems
US20070024388A1 (en) * 2005-07-27 2007-02-01 Hassan Tanbakuchi Slabline structure with rotationally offset ground
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
BRPI0807046A2 (pt) 2007-02-09 2015-05-26 Tranzyme Pharma Inc Composto, composição farmacêutica, métodos de tratar um distúrbio, uma doença cardiovascular e um paciente que sofre de motilidade gastrointestinal reduzida ou disfuncional e, kit.
US7862825B2 (en) * 2007-02-21 2011-01-04 Mladen Vranic Method of controlling tight blood glucose by somatostatin receptor antagonists
AR086554A1 (es) 2011-05-27 2014-01-08 Novartis Ag Derivados de la piperidina 3-espirociclica como agonistas de receptores de la ghrelina
AU2013255458A1 (en) 2012-05-03 2014-10-09 Novartis Ag L-malate salt of 2, 7 - diaza - spiro [4.5 ] dec- 7 - yle derivatives and crystalline forms thereof as ghrelin receptor agonists
CN105164129B (zh) 2013-05-28 2018-01-19 拉夸里亚创药株式会社 多晶型物形式
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
JP6051392B1 (ja) * 2014-08-05 2016-12-27 ラクオリア創薬株式会社 グレリン受容体アゴニストとしてのセリン誘導体
EP3212648A1 (en) * 2014-10-31 2017-09-06 RaQualia Pharma Inc. Tetrahydropyrazolopyridine derivatives as ghrelin receptor agonists
US20170121385A1 (en) 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Methods of treating neurodegenerative conditions

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3235550A (en) 1966-02-15 Anal g gesiaxoat t tail intravenous injection
US3190802A (en) 1961-10-09 1965-06-22 Boehringer Sohn Ingelheim Shaving composition and method of using same
US4411890A (en) 1981-04-14 1983-10-25 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
GB2101114B (en) 1981-07-10 1985-05-22 Farmos Group Ltd Substituted imidazole derivatives and their preparation and use
US5242783A (en) 1991-07-31 1993-09-07 Eastman Kodak Company Photographic material and process
CA2147503A1 (en) 1992-11-06 1994-05-26 Judith M. Pisano Substituted dipeptide analogs promote release of growth hormone
RU2168512C2 (ru) 1992-12-11 2001-06-10 Мерк Энд Ко., Инк. Спиропиперидины, способы их получения (варианты)
EP0739204A4 (en) 1993-11-09 2000-03-15 Merck & Co Inc PIPERIDINE, PYRROLIDINE AND HEXAHYDRO-1H-AZEPINE SUPPORT THE RELEASE OF THE GROWTH HORMONE
US5492916A (en) * 1993-12-23 1996-02-20 Merck & Co., Inc. Di- and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
BR9610277A (pt) 1995-08-31 1999-07-06 Schering Corp Derivados de piperazino como antagonistas de neurowuinina
EP0766966A3 (en) 1995-09-08 2001-02-28 Eli Lilly And Company Method of treating insulin resistance
PL327227A1 (en) 1995-12-22 1998-12-07 Novo Nordisk As Compounds exhibiting growth hormone liberating properties
TW432073B (en) 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
UA53716C2 (uk) 1997-06-25 2003-02-17 Пфайзер Продактс Інк. Тартратна сіль заміщеного дипептиду, спосіб її одержання, проміжні сполуки та спосіб їх одержання, фармацевтична композиція (варіанти), спосіб підвищення рівнів ендогенного гормону росту та спосіб лікування або профілактики захворювань (варіанти)
AU7445498A (en) * 1997-06-25 1999-01-04 Pfizer Inc. Dipeptide derivatives as growth hormone secretagogues
UA64751C2 (uk) 1997-06-25 2004-03-15 Пфайзер Продактс Інк. Спосіб лікування інсулінової толерантності речовинами, які посилюють секрецію гормону росту (варіанти) та фармацевтична композиція (варіанти)

Also Published As

Publication number Publication date
WO1998058949A1 (en) 1998-12-30
HUP0001922A2 (hu) 2000-12-28
IL154112A0 (en) 2003-07-31
ATE305477T1 (de) 2005-10-15
IN189724B (es) 2003-04-19
HRP980361A2 (en) 1999-02-28
EP1000085B1 (en) 2005-09-28
AU7445698A (en) 1999-01-04
CN1530107A (zh) 2004-09-22
US20030100561A1 (en) 2003-05-29
IL156465A (en) 2004-07-25
AP1145A (en) 2003-02-14
KR20010014224A (ko) 2001-02-26
AP9801267A0 (en) 1998-06-30
IL154116A0 (en) 2003-07-31
ZA985546B (en) 2000-01-10
IL133626A0 (en) 2001-04-30
AU747510B2 (en) 2002-05-16
JP2000514099A (ja) 2000-10-24
IS5275A (is) 1999-11-26
IL154115A0 (en) 2003-07-31
BR9810477A (pt) 2007-05-22
SK175699A3 (en) 2001-04-09
BG104008A (en) 2000-07-31
OA11242A (en) 2003-07-23
US6630487B2 (en) 2003-10-07
DZ2539A1 (fr) 2003-02-08
EA199901075A1 (ru) 2000-08-28
TW553943B (en) 2003-09-21
JP3742643B2 (ja) 2006-02-08
NO996205D0 (no) 1999-12-15
YU70199A (sh) 2003-01-31
HUP0001922A3 (en) 2001-02-28
PA8452601A1 (es) 2000-05-24
CO4950621A1 (es) 2000-09-01
HK1028051A1 (en) 2001-02-02
HN1998000088A (es) 1999-01-08
IL154114A0 (en) 2003-07-31
CN1259140A (zh) 2000-07-05
EA002089B1 (ru) 2001-12-24
IL156465A0 (en) 2004-01-04
US6867202B1 (en) 2005-03-15
ES2248899T3 (es) 2006-03-16
EG21712A (en) 2002-02-27
ID24345A (id) 2000-07-13
CN1152049C (zh) 2004-06-02
NO996205L (no) 1999-12-15
TNSN98113A1 (fr) 2005-03-15
DE69831745T2 (de) 2006-08-31
EP1000085A1 (en) 2000-05-17
IL154111A0 (en) 2003-07-31
TR199903257T2 (xx) 2000-12-21
AR012256A1 (es) 2000-09-27
DE69831745D1 (de) 2006-02-09
PL337659A1 (en) 2000-08-28
UA64751C2 (uk) 2004-03-15
JP2005097261A (ja) 2005-04-14
CA2294464A1 (en) 1998-12-30
NZ500655A (en) 2002-02-01
US6448263B1 (en) 2002-09-10
MA24581A1 (fr) 1998-12-31

Similar Documents

Publication Publication Date Title
PE105399A1 (es) PROCEDIMIENTO PARA LA PREPARACION DE DERIVADOS DE 3a-(R)-BENCIL-2-METIL-2,3,3a,4,5,6,7-HEXAHIDRO-PIRAZOLO[4,3-c]PIRIDINA-3-ONA
PE20010574A1 (es) Derivados de indol como ligandos del receptor 5-ht2
PE20060627A1 (es) Derivados de pirazol condensado como agonistas de los receptores cannabinoides cb1 y/o cb2
DE3887307D1 (de) Sulfhydryl enthaltende tricylische Lactame und ihre pharmakologische Verwendung.
PE20010613A1 (es) Antagonistas de la hormona concentradora de la melanina
PE20070336A1 (es) Compuestos de indolina como agonistas de receptores adrenergicos alfa2c funcionalmente selectivos
KR880002834A (ko) α-알킬-4-아미노-3-퀴놀린메탄올 및 1-(4-아르알킬아미노-3-퀴놀리닐) 알칸온, 이의 제조방법 및 약제로서의 용도
CO4480108A1 (es) Compuestos dipeptidos que son secretagogos de la hormona del crecimiento
AR057771A1 (es) Agonistas adrenoreceptores alfa2c
PE20021067A1 (es) Empleo de antagonistas del receptor nk3
KR880012227A (ko) 도파민 수용체 길항제의 신규사용법
PE20001084A1 (es) Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas
ES2084339T3 (es) Tetrahidropiridinas e hidroxipiperidinas sustituidas utiles como agentes para el sistema nervioso central.
KR900016196A (ko) 테트라하이드로벤즈[c, d]인돌 세로토닌 효능제
ES2032570T3 (es) Derivados antiparkinson de ergolina. (reserva del art. 167.2 cpe).
ES2184083T3 (es) Derivados de acilaminoalquenilen-amida como antagonistas de nk1 y nk2.
DK131084A (da) Egolinderivater, fremgangsmaade til fremstilling heraf samt anvendelsen heraf som laegemiddel
AR006719A1 (es) Derivados de bencilamina y formulacion farmaceutica que comprende a uno de dichos derivados.
NO173869C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 1,7-kondenserte 1h-indol-2-carboxylsre-n-(1,4-benzodiazepin-3-yl)-amider
KR950000146A (ko) 테트라하이드로벤즈[cd]인돌-6-카복스아미드를 사용한 구토 예방 및 성기능부전의 치료방법
ES2184989T3 (es) Derivados de feniletanolaminotetralincarboxamida 3,4-disustituidos.
ATE183085T1 (de) Behandlung und regulierung der augenentwicklung mit cholinergischen agonisten
ES2172029T3 (es) 3-amino-1-cianofenil-uracilos.
UA41329C2 (uk) Фармацевтична композиція для лікування порушень серцевого ритму у великих ссавців та людей, похідні 3-фенілсульфоніл-3,7-діазабіцикло[3,3,1]нонану та лікарський засіб для лікування аритмії
WO2003051291A3 (en) Substituted 5-hydroxy-indole compounds for the treatment of glaucoma

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed